• Title of article

    Path to Personalized Medicine for Type 2 Diabetes Mellitus: Reality and Hope

  • Author/Authors

    Aghaei Meybodi، Hamid Reza نويسنده Osteoporosis Research Center, Endocrinology and Metabolism Clinical Sciences Institute. Tehran University of Medical Sciences, Tehran. Iran , , Hasanzad، Mandana نويسنده Tehran Medical Branch, Islamic Azad University, Tehran , , Larijani، Bagher نويسنده ,

  • Issue Information
    ماهنامه با شماره پیاپی 0 سال 2017
  • Pages
    9
  • From page
    166
  • To page
    174
  • Abstract

    Type 2 diabetes mellitus (T2DM) is recognized as a public health problem and increasingly prevalent illness. Key elements of the guideline for diabetes care are based on evidence-based medicine approach and apply for population, not individuals. However, individualized care can improve diabetes management. Personalized medicine is otherwise called precision medicine tries to find better prediction, prevention, and intervention for T2DM individuals. Precision medicine in diabetes refers to the utility of genomics data of a patient with diabetes to provide the most effective diagnosis strategies and treatment plans. Over 100 genetic loci influence susceptibility to T2DM. Genomics data together with the potential of other “Omics” and clinical evidence-based data will lead to diabetes care improvement in the context of personalized medicine in the near future. Breakthrough of technologies enables much greater improvements in the understanding of individual variations that may alter the T2DM outcome. This article represents a comprehensive review of current knowledge on the impact of personalized medicine in T2DM.

  • Journal title
    Acta Medica Iranica
  • Serial Year
    2017
  • Journal title
    Acta Medica Iranica
  • Record number

    2404565